<DOC>
	<DOCNO>NCT02942498</DOCNO>
	<brief_summary>The purpose study determine vitamin C vitamin E combination effective treatment cognitive behavior disorder child fragile X syndrome .</brief_summary>
	<brief_title>Clinical Trial Asses Safety Efficacy Vitamin C Vitamin E Combination Versus Placebo Treating Cognitive Behavior Disorder Children With Fragile X Syndrome</brief_title>
	<detailed_description>The combination vitamin E vitamin C supplementation associate low prevalence ( -78 % ) incidence ( -64 % ) Alzheimer 's disease elderly population . It recently show dietary vitamin E supplementation reduces production free radical inhibit NADPH oxidase activity circulate neutrophil . Another work describe inhibition glutamate release activate microglia cell culture incubate vitamin E , effect prevent excitotoxicity . The investigator propose evaluate effectiveness treatment neurodevelopmental disorder affect fragile X syndrome ( FXS ) lipophilic compound antioxidant tocopherol hydrophilic compound antioxidant ascorbic acid , regulate oxidative stress improve learn behavioral mouse model human . Our group positive result use combination antioxidant treatment fragile X syndrome adolescent . This disease develop previous clinical trial EUDRACT code : 2009-017837-23 2013-004276-35 . The use combination vitamin C E treatment cognitive behavioral disorder FXS , patent PCT-050 187 reference number 2011070875 This combination administer single oral dose total dose 10mg / kg / day vitamin . This dose maintain within therapeutic range antioxidant .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Fragile X Syndrome</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Child Behavior Disorders</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin E</mesh_term>
	<mesh_term>Tocopherols</mesh_term>
	<mesh_term>Tocotrienols</mesh_term>
	<mesh_term>alpha-Tocopherol</mesh_term>
	<mesh_term>Ascorbic Acid</mesh_term>
	<criteria>1 . Diagnosis Fragile X syndrome genetic test molecular biology , full mutation result methylation . 2 . Having old age 1 year less 9 year 3 . Having sign informed consent document start participation trial . 1 . Any advanced , severe unstable disease . 2 . Individuals psychiatric diagnosis first diagnosis . 3 . It suffer serious medical problem last 12 month . 4 . Be take 100 mg vitamin E C day last month . 5 . Having physical , mental sensory impairment prevent assessment effectiveness . 6 . Hypersensitivity component preparation . 7 . Liver failure severe renal previous history kidney stone . 8 . Any treatment regimen , include treatment psychotropic drug / anticonvulsant therapy stable period â‰¥ 4 week randomization . 9 . Current treatment two psychoactive medication , exclude medication use specifically control seizure . 10 . Hypoprothrombinemia secondary vitamin K deficiency 11 . Sensitivity compound formula treatment . 12 . Patients diagnose congenital idiopathic methemoglobinemia diagnosis glucose6phosphate dehydrogenase deficiency . 13 . Use oral anticoagulant , iron vitamin A . 14 . Forecast initiate change pharmacological pharmacological intervention course study . 15 . Patients weigh less 4.2 kg</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>8 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>behavior , cognitive</keyword>
</DOC>